The DHHS will allocate 1 million doses of Sanofi-Pasteur’s injectable multi-dose inactivated H1N1 vaccine (indicated for ages 6 months and up) for DoD to distribute using its own medical logistics infrastructure. The Defense Logistics Agency (DLA) will receive this vaccine into its depot system and ship according to OSD(HA) and Service priorities. This vaccine is intended for DoD’s non-beneficiary workforce and OCONUS DoD beneficiaries. Vaccine is scheduled to begin arriving at the DLA depot mid-October and continue until a total of one million doses is allotted.
LTC Patrick Garman, PhD, Deputy Director, MILVAX
This vaccine, in the amount of 2.7 Million doses for use by DoD Uniformed Service Members, will consist of Novartis injectable multi-dose inactivated vaccine indicated for ages 4 years and up. This vaccine is being released on a timeline comparable to the other injectable inactivated products. Small amounts of vaccine (in the hundred thousand dose range) are scheduled for release the end of October, but large amounts will not be available until early November.
Please remember that priority for intitial doses are deployed and deploying troops, and other high-risk Service Members.
This is the main distribution system for the US, and is seen by the DHHS as being vital to the Federal Government’s ability to respond to future pandemics that may have a more deadly presentation. The allocation of vaccine is based on the population of each state. Each state hosts a website where medical providers register to become immunizers. DoD military treatment facilities (MTFs) must participate in this system in order to receive vaccine for their non-uniformed beneficiaries. Vaccine distributed through this route consists of all five manufacturer’s products.
Presently, MedImmune’s intranasal product is being distributed to the states. This is due to a faster manufacturing process which consistently allows MedImmune to market its product before other manufacturers. Vaccine received by MTFs through this system is intended for DoD’s non-uniformed beneficiaries.
The Department of Health and Human Services (DHHS) was directed by the President of the United States to contract with manufacturers to produce enough H1N1 vaccine for those who wish to be immunized. DHHS has estimated there will eventually be close to 250 million doses available. This amount will be a mixture of products from Sanofi-Pasteur, Novartis Vaccines and Diagnostics Limited, CSL Limited, GlaxoSmithKline, and MedImmune LLC.
DoD will receive vaccine from DHHS, from 3 different pools or allotments:
Please note that vaccine should be used according to the different target groups and allotments.
The Live Inactivated Influenza Vaccine (LAIV) is administered intranasally. There is both a seasonal and novel H1N1 LAIV product. The following are various scenarios in which the intranasal vaccine can be administered: